$13.16
+1.09 (+9.03%)
Open$12.31
Previous Close$12.07
Day High$13.80
Day Low$12.25
52W High$29.91
52W Low$24.38
Volume—
Avg Volume614.4K
Market Cap280.89M
P/E Ratio48.31
EPS$0.57
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+164.0% upside
Current
$13.16
$13.16
Target
$34.74
$34.74
$25.90
$34.74 avg
$38.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 29.07M | 27.10M | 30.53M |
| Net Income | 5.84M | 4.59M | 6.02M |
| Profit Margin | 20.1% | 16.9% | 19.7% |
| EBITDA | 8.15M | 7.65M | 7.71M |
| Free Cash Flow | 6.21M | 7.09M | 6.33M |
| Rev Growth | +18.1% | +12.4% | +4.7% |
| Debt/Equity | 0.64 | 0.68 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |